Search clinical trials for: plerixafor

Total 164 results

National Heart, Lung, and Blood Institute (NHLBI)

Completed

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

Healthy

United States
Stephen Couban
Genzyme, a Sanofi Company

Completed

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

Malignant Lymphoma, Stem Cell Type

Canada
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Multiple Myeloma and Malignant Lymphoma

Japan
Peking University

Recruiting

Plerixafor for Poorly Mobilized Lymphoma

Lymphoma

China
Genzyme, a Sanofi Company
Sanofi

Completed

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Neuroblastoma | Brain Tumors | Ewing's Sarcoma/Soft Tissue Sarcoma

Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
University Hospital, Clermont-Ferrand

Completed

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)

Children Cancer, Solid Tumor

France
University of Washington

Completed

AMD 3100 for Treatment of Myelokathexis

Neutropenia

United States
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
National Institute of Allergy and Infectious Diseases...
Lombardi Comprehensive Cancer Center

Terminated

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

Cancer

United States
Genzyme, a Sanofi Company

Completed

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Renal Impairment

United States
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

Lymphoma

Japan
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Lymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant Complications

Mexico
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection

Acute Myeloid Leukemia

Canada
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

Germany
Genzyme, a Sanofi Company

Approved for marketing

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)

Autologous Stem Cell Transplant
University of Liverpool
Genzyme, a Sanofi Company

Unknown

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) (PHANTASTIC)

Lymphoma | Lymphoproliferative Disorders | Multiple Myeloma | Plasma Cell Dyscrasia

United Kingdom
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

Lymphoma, Non-Hodgkin | Multiple Myeloma

Canada
Hospital Universitari Vall d'Hebron Research Institute
CIEMAT; CIBERER

Completed

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Fanconi Anemia

Spain
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Genzyme, a Sanofi Company

Completed

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Healthy Volunteer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Prospective Observational Study on Plerixafor After Chemotherapy

Lymphoma | Myeloma

Italy
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
Genzyme, a Sanofi Company
AnorMED

Terminated

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Multiple Myeloma

United States
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Autologous Stem Cell Transplantation

United States
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
E. Steve Woodle
Sanofi-Synthelabo

Unknown

Quantitating the Impact of Plerixafor

Transplants and Implants

United States
Federal Research Institute of Pediatric Hematology...

Unknown

A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Hematopoietic Stem Cell Transplantation | Wiskott-Aldrich Syndrome | Graft Failure

Russian Federation
French Innovative Leukemia Organisation
Genzyme, a Sanofi Company; Acute Leukemia French Association

Terminated

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (PRIMAL)

Acute Myeloid Leukemia

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Refractory Multiple Myeloma

United States
Ensoma

Completed

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Healthy Volunteers

United States
4Living Biotech

Withdrawn

Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) (LEONARDO)

COVID-19 | COVID-19 Acute Respiratory Distress Syndrome

France, Bulgaria
Celldex Therapeutics

Terminated

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML) | Non-Hodgkins Lymphoma (NHL) | For Donors | Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | For Recipients and other conditions

United States
Genzyme, a Sanofi Company

Terminated

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
Duke University
Genzyme, a Sanofi Company

Completed

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

Multiple Myeloma | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Lymphoma | Multiple Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Hodgkin's Disease

United States
University Hospital Inselspital, Berne

Completed

PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma (PAV)

Myeloma

Switzerland
University of Colorado, Denver
Sanofi

Completed

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

Pulmonary Fibrosis | Cystic Fibrosis | COPD

United States
Genzyme, a Sanofi Company

Completed

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Genzyme, a Sanofi Company

Completed

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Non-Hodgkin's Lymphoma

Korea, Republic of, Taiwan, United States, Canada
Weill Medical College of Cornell University
Genzyme, a Sanofi Company

Completed

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Alder Hey Children's NHS Foundation Trust

Withdrawn

Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery (PHOXEY)

Cardiac Event
Shandong University
Tianjin Central Hospital of Gynecology Obstetrics

Recruiting

Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates

Infectious Disease

China
University of California, San Francisco

Terminated

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

Severe Combined Immunodeficiency

United States
Fondazione EMN Italy Onlus

Completed

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Multiple Myeloma

Italy
Assistance Publique - Hôpitaux de Paris

Completed

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (DrepaMob)

Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia

France
Tel-Aviv Sourasky Medical Center
Sanofi

Unknown

Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. (GCSF)

Autologous Stem Cell Transplantation
Federal Research Institute of Pediatric Hematology...

Unknown

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Chronic Granulomatous Disease

Russian Federation

Search clinical trials for: plerixafor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations